Form 4 for FULC Fulcrum Therapeutics, Inc.

Accepted 2021-09-24 00:00:00 ET · period of report 2021-09-22 · accession 0000899243-21-037615 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
I	2021-09-24	2021-09-22	FULC	LEVIN MARK J	Dir, 10%	J - Other	—	-1.00M	4.96M	-17%	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-09-22	J	D	1,000,000	—	4,962,202	I See footnote	—	—	(F1) Pursuant to a 10b5-1 trading plan adopted on March 30, 2021 by Third Rock Ventures III, L.P. ("TRV III"), TRV III distributed for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") on September 22, 2021, to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. (F2) The Reporting Person is a partner of TRV GP III, which is the general partner of TRV III. The Reporting Person disclaims beneficial ownership over the shares held by TRV III, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.